Poolbeg Pharma plc

Further strengthens Poolbeg's robust intellectual property portfolio

Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.

Poolbeg Pharma plc, headquartered in London and listed on AIM, is running a UK-based clinical trial of POLB 001 to test its ability to prevent cancer immunotherapy-induced cytokine release syndrome (CRS)—a major bottleneck to the wider rollout of breakthrough cancer immunotherapies.

Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.

Poolbeg Pharma announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg's Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.  

Poolbeg Pharma will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme which will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.

Poolbeg Pharma announces key insights from its poster presentation at the 66th American Society of Hematology ('ASH') Annual Meeting and Exposition, San Diego, California.